Lori Englebert

“So the blinded period is through 26 weeks, so that was through our Part B. We did just release Part C data, which took us out to 12 months. And that was open label from 26 weeks out to fully one year.”

“I will just open up by saying and echoing Samat's comments that this is a very, very exciting time for Compass and Comp 360 as we are, as some may say, barreling towards a potential filing date and potential approval.”

“As Kabir outlined, we have achieved significant milestones in the first half of the year. Notably, advanced important commercial readiness initiatives across organizational capabilities, strategic collaborations, policy and payer engagement, and distribution.”

“So, Steve, anything you want to add on that? In terms of the Spravato patients being treated in academic centers versus the more what everyone calls the interventional psychiatry treatment centers, the academic centers are treating very, very small portion.”

“Yeah, I think, you know, what Guy said in terms of the purpose of the support model is that we are making sure that patients have support through, you know, drug administration, as well as prior to drug administration and after drug administration.”